JP2024547131A5 - - Google Patents

Info

Publication number
JP2024547131A5
JP2024547131A5 JP2024538287A JP2024538287A JP2024547131A5 JP 2024547131 A5 JP2024547131 A5 JP 2024547131A5 JP 2024538287 A JP2024538287 A JP 2024538287A JP 2024538287 A JP2024538287 A JP 2024538287A JP 2024547131 A5 JP2024547131 A5 JP 2024547131A5
Authority
JP
Japan
Prior art keywords
disorder
alkyl
fluoroalkyl
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024547131A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/082403 external-priority patent/WO2023129909A1/en
Publication of JP2024547131A publication Critical patent/JP2024547131A/ja
Publication of JP2024547131A5 publication Critical patent/JP2024547131A5/ja
Pending legal-status Critical Current

Links

JP2024538287A 2021-12-27 2022-12-27 セロトニン受容体のアミノテトラリン活性化剤 Pending JP2024547131A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163294030P 2021-12-27 2021-12-27
US63/294,030 2021-12-27
PCT/US2022/082403 WO2023129909A1 (en) 2021-12-27 2022-12-27 Aminotetraline activators of serotonin receptors

Publications (2)

Publication Number Publication Date
JP2024547131A JP2024547131A (ja) 2024-12-26
JP2024547131A5 true JP2024547131A5 (cg-RX-API-DMAC7.html) 2025-12-23

Family

ID=86898315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538287A Pending JP2024547131A (ja) 2021-12-27 2022-12-27 セロトニン受容体のアミノテトラリン活性化剤

Country Status (6)

Country Link
US (3) US11827580B2 (cg-RX-API-DMAC7.html)
EP (1) EP4457203A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024547131A (cg-RX-API-DMAC7.html)
AU (1) AU2022425198A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242479A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023129909A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
JP2024520832A (ja) 2021-06-08 2024-05-24 エンセオジェニックス バイオサイエンシズ, インコーポレイテッド セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス,インク. フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
CA3242479A1 (en) * 2021-12-27 2023-07-06 Atai Therapeutics, Inc. AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS
WO2024124056A1 (en) * 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045180B2 (ja) * 1977-05-17 1985-10-08 第一製薬株式会社 2−アミノテトラリン誘導体
FR2691145A1 (fr) 1992-05-18 1993-11-19 Inst Nat Sante Rech Med Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
NZ510988A (en) 1998-10-07 2005-01-28 Ortho Mcneil Pharm Inc N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
HUP0202143A3 (en) 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
MX2008015843A (es) 2006-06-20 2009-01-09 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos.
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
CA2686994A1 (en) 2007-05-11 2008-11-20 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
BRPI0919920A2 (pt) 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US20120283298A1 (en) 2009-10-16 2012-11-08 Albert Michael Crider Methods for treating memory impairment
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
GB201409516D0 (en) 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US10454900B2 (en) 2015-09-25 2019-10-22 Mcafee, Llc Remote authentication and passwordless password reset
WO2018094005A1 (en) 2016-11-16 2018-05-24 The General Hospital Corporation Myeloperoxidase imaging agents
EP3700935A4 (en) 2017-10-25 2021-08-04 University Of South Florida INGREDIENT-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
CA3079819C (en) 2017-11-06 2023-03-14 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
EP3841085B1 (en) 2018-08-22 2026-05-06 University Of Technology Sydney Nbome test
US12318357B2 (en) 2019-08-02 2025-06-03 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation
US11660305B2 (en) 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
US12534425B2 (en) 2020-06-29 2026-01-27 Gilgamesh Pharmaceuticals, Inc. Phenalkylamines and methods of treating mood disorders
DK4172145T3 (da) 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
JP2024512796A (ja) 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク. サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
CA3217737A1 (en) 2021-05-11 2022-11-17 Jason WALLACH Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders
WO2022261263A1 (en) 2021-06-08 2022-12-15 Gilgamesh Pharmaceuticals, Inc. Methods of treating neuropsychiatric disorders
JP2024520832A (ja) 2021-06-08 2024-05-24 エンセオジェニックス バイオサイエンシズ, インコーポレイテッド セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
MX2024007220A (es) 2021-12-15 2024-08-27 Delix Therapeutics Inc Psicoplastogenos de pirrolidina fusionada y sus usos.
CA3242479A1 (en) 2021-12-27 2023-07-06 Atai Therapeutics, Inc. AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS
WO2024124056A1 (en) 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
EP4637735A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
EP4637736A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
WO2024192150A2 (en) 2023-03-16 2024-09-19 Atai Therapeutics Inc. 3-alkylamine indole activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Similar Documents

Publication Publication Date Title
JP2023058575A5 (cg-RX-API-DMAC7.html)
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2022501327A5 (cg-RX-API-DMAC7.html)
JP2025524914A5 (cg-RX-API-DMAC7.html)
JP2004534816A5 (cg-RX-API-DMAC7.html)
JP2022522694A5 (cg-RX-API-DMAC7.html)
JP2002520416A5 (cg-RX-API-DMAC7.html)
JP2020075939A5 (cg-RX-API-DMAC7.html)
JP2024541569A5 (cg-RX-API-DMAC7.html)
JP2024512425A5 (cg-RX-API-DMAC7.html)
JPWO2023195530A5 (cg-RX-API-DMAC7.html)
JP2012508251A5 (cg-RX-API-DMAC7.html)
JP2001517627A (ja) 敵対的反抗障害の処置法
JP2021513547A5 (cg-RX-API-DMAC7.html)
JP2005517677A5 (cg-RX-API-DMAC7.html)
JP2025507915A5 (cg-RX-API-DMAC7.html)
JP2023517920A5 (cg-RX-API-DMAC7.html)
JP2011518176A5 (cg-RX-API-DMAC7.html)
JP2016537432A5 (cg-RX-API-DMAC7.html)
JP2022551691A5 (cg-RX-API-DMAC7.html)
JP2004525178A5 (cg-RX-API-DMAC7.html)